Compare PETS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PETS | ANIX |
|---|---|---|
| Founded | 1996 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 100.6M |
| IPO Year | 2003 | 2013 |
| Metric | PETS | ANIX |
|---|---|---|
| Price | $2.25 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 60.1K | ★ 111.0K |
| Earning Date | 06-09-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $2.44 |
| 52 Week High | $4.32 | $5.46 |
| Indicator | PETS | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 43.41 |
| Support Level | $2.19 | $2.81 |
| Resistance Level | $2.44 | $3.12 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 16.63 | 15.28 |
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.